bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure.S5 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Authors: Lone Waseem , Bouska Alyssa , Sharma Sunandini , Amador Catalina , Saumyaranjan Mallick , Herek Tyler A. , Heavican Tayla B. , Yu Jiayu , Lim Soon Thye , Ong Choon Kiat , Slack Graham W. , Savage Kerry J. , Rosenwald Andreas , Ott German , Cook James R. , Feldman Andrew L. , Rimsza Lisa M. , McKeithan Timothy W. , Greiner Timothy C. , Weisenburger Dennis D. , Melle Federica , Motta Giovanna , Pileri Stefano , Vose Julie M. , Chan Wing C. , Iqbal Javeed
Published: April 2023

Figure S5: Validation of nCounter signature genes in a qRT-PCR-based cohort. Relative expression of miRNA identified on the nCounter panel as being high in AITL (top panel), PTCL-TBX21 (middle panel), or PTCL-GATA3 (bottom panel). Data are expressed by the median centered Ct value and lower values correspond to higher expression.
Figure.S4 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Authors: Lone Waseem , Bouska Alyssa , Sharma Sunandini , Amador Catalina , Saumyaranjan Mallick , Herek Tyler A. , Heavican Tayla B. , Yu Jiayu , Lim Soon Thye , Ong Choon Kiat , Slack Graham W. , Savage Kerry J. , Rosenwald Andreas , Ott German , Cook James R. , Feldman Andrew L. , Rimsza Lisa M. , McKeithan Timothy W. , Greiner Timothy C. , Weisenburger Dennis D. , Melle Federica , Motta Giovanna , Pileri Stefano , Vose Julie M. , Chan Wing C. , Iqbal Javeed
Published: April 2023

Figure S4: Principal component analysis and hierarchical clustering (HC) of PTCL subgroups. A. PCA of PTCL subgroups and CD3+ T cells based on miRNA expression quantified using with the qRT-PCR platform (ABI, Inc).B. HC based on expression of miRNA in the nCounter signatures in PTCL subtypes and CD3+ T cells profiled with the qRT-PCR platform (ABI, Inc). C. Scatter plot of microRNA expression between n-Counter and ABI qRT-PCR platforms in 4 PTCL cases profiled on both platforms. miRNA-126 and miRNA-145 are colored in red and blue, respectively. miRNA that showed skewed expression (were in the upper quartile in a case on 1 platform, but in the lower quartile for that case when measured by other platform) are noted by the other colored dots. D. Supervised clustering on ABI platform using the differentially expressed genes of PTCL subtypes obtained from n-Counter
Figure S1 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Authors: Arai Hiroyuki , Elliott Andrew , Xiu Joanne , Wang Jingyuan , Battaglin Francesca , Kawanishi Natsuko , Soni Shivani , Zhang Wu , Millstein Joshua , Sohal Davendra , Goldberg Richard M. , Hall Michael J. , Scott Aaron J. , Khushman Moh'd , Hwang Jimmy J. , Lou Emil , Weinberg Benjamin A. , Marshall John L. , Lockhart Albert C. , Stafford Phillip , Zhang Jian , Moretto Roberto , Cremolini Chiara , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

POLE and DDR mutations in MSS/pMMR patients
Figure.S1 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma
Authors: Lone Waseem , Bouska Alyssa , Sharma Sunandini , Amador Catalina , Saumyaranjan Mallick , Herek Tyler A. , Heavican Tayla B. , Yu Jiayu , Lim Soon Thye , Ong Choon Kiat , Slack Graham W. , Savage Kerry J. , Rosenwald Andreas , Ott German , Cook James R. , Feldman Andrew L. , Rimsza Lisa M. , McKeithan Timothy W. , Greiner Timothy C. , Weisenburger Dennis D. , Melle Federica , Motta Giovanna , Pileri Stefano , Vose Julie M. , Chan Wing C. , Iqbal Javeed
Published: April 2023

Figure S1: Clinical outcome of PTCL entities and molecular characterization (A) Heatmap of AITL, PTCL-TBX21 and PTCL-GATA3 classification signatures profiled with the HG-U133 Plus2 platform (n=42); X-axis genes, Y-axis cases (B) Kaplan-Meier curves comparing OS between the PTCL subgroups.
Supplementary Table S5 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Authors: Subbiah Vivek , Gainor Justin F. , Oxnard Geoffrey R. , Tan Daniel S.W. , Owen Dwight H. , Cho Byoung Chul , Loong Herbert H. , McCoach Caroline E. , Weiss Jared , Kim Yu Jung , Bazhenova Lyudmila , Park Keunchil , Daga Haruko , Besse Benjamin , Gautschi Oliver , Rolfo Christian , Zhu Edward Y. , Kherani Jennifer F. , Huang Xin , Kang Suhyun , Drilon Alexander
Published: April 2023

TEAEs and TRAEs occurring in pts with intracranial disease
Supplementary Data from A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors
Authors: Lei Xinyuan , Ou Zhanpeng , Yang Zhaohui , Zhong Jianglong , Zhu Yanliang , Tian Jing , Wu Jiannan , Deng Heran , Lin Xinyu , Peng Yu , Li Bowen , He Lile , Tu Zhiming , Chen Weixiong , Li Qunxing , Liu Niu , Zhang Hanqing , Wang Zhangsong , Fang Zezhen , Yamada Teppei , Lv Xiaobin , Tian Tian , Pan Guokai , Wu Fan , Xiao Liping , Zhang Lizao , Cai Tingting , Wang Xinhui , Tannous Bakhos A. , Li Jinsong , Kontos Filippos , Ferrone Soldano , Fan Song
Published: April 2023

Supplementary methods, tables and figures
Supplementary Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Authors: Subbiah Vivek , Gainor Justin F. , Oxnard Geoffrey R. , Tan Daniel S.W. , Owen Dwight H. , Cho Byoung Chul , Loong Herbert H. , McCoach Caroline E. , Weiss Jared , Kim Yu Jung , Bazhenova Lyudmila , Park Keunchil , Daga Haruko , Besse Benjamin , Gautschi Oliver , Rolfo Christian , Zhu Edward Y. , Kherani Jennifer F. , Huang Xin , Kang Suhyun , Drilon Alexander
Published: April 2023

LIBRETTO-001 Investigators List
Table S6 from Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Authors: Ewing Ailith , Meynert Alison , Churchman Michael , Grimes Graeme R. , Hollis Robert L. , Herrington C. Simon , Rye Tzyvia , Bartos Clare , Croy Ian , Ferguson Michelle , Lennie Mairi , McGoldrick Trevor , McPhail Neil , Siddiqui Nadeem , Dowson Suzanne , Glasspool Rosalind , Mackean Melanie , Nussey Fiona , McDade Brian , Ennis Darren , McMahon Lynn , Matakidou Athena , Dougherty Brian , March Ruth , Barrett J. Carl , McNeish Iain A. , Biankin Andrew V. , Roxburgh Patricia , Gourley Charlie , Semple Colin A.
Published: April 2023

SNVs in non-BRCA1/2 HR genes
Supplementary Video S2 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
Authors: Xiao Lin , Somers Klaartje , Murray Jayne , Pandher Ruby , Karsa Mawar , Ronca Emma , Bongers Angelika , Terry Rachael , Ehteda Anahid , Gamble Laura D. , Issaeva Natalia , Leonova Katerina I. , O'Connor Aisling , Mayoh Chelsea , Venkat Pooja , Quek Hazel , Brand Jennifer , Kusuma Frances K. , Pettitt Jessica A. , Mosmann Erin , Kearns Adam , Eden Georgina , Alfred Stephanie , Allan Sophie , Zhai Lei , Kamili Alvin , Gifford Andrew J. , Carter Daniel R. , Henderson Michelle J. , Fletcher Jamie I. , Marshall Glenn , Johnstone Ricky W. , Cesare Anthony J. , Ziegler David S. , Gudkov Andrei V. , Gurova Katerina V. , Norris Murray D. , Haber Michelle
Published: April 2023

HT10806TG_CBL0137 treatment
Supplementary Table 1 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
Authors: de Bono Johann S. , Fleming Mark T. , Wang Judy S. , Cathomas Richard , Miralles Manuel Selvi , Bothos John , Hinrichs Mary Jane , Zhang Qu , He Peng , Williams Marna , Rosenbaum Anton I. , Liang Meina , Vashisht Kapil , Cho Song , Martinez Pablo , Petrylak Daniel P.
Published: April 2023

Clinical antitumor activity summary
Figure S4 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Authors: Krumbholz Manuela , Eiblwieser Johanna , Ranft Andreas , Zierk Jakob , Schmidkonz Christian , Stütz Adrian M , Peneder Peter , Tomazou Eleni M. , Agaimy Abbas , Bäuerle Tobias , Hartmann Wolfgang , Dirksen Uta , Metzler Markus
Published: April 2023

Quantified mean ctDNA levels (fusion gene/ALB copies) before (VIDE1A) and after (VIDE1E) the first chemotherapy block separated according to different clinical risk criteria. The upper graphs show results for localized disease, the lower graphs show results for metastatic disease.
Table S2 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Table S2
Figure S4 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Figure S4. ATRA-TCP induces the expression of a RA-responsive gene signature in patient responders.
Figure S1 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
Authors: Kist de Ruijter Laura , Hooiveld-Noeken Jahlisa S. , Giesen Danique , Lub-de Hooge Marjolijn N. , Kok Iris C. , Brouwers Adrienne H. , Elias Sjoerd G. , Nguyen Margaret T.L. , Lu Hong , Gietema Jourik A. , Jalving Mathilde , de Groot Derk J.A. , Vasiljeva Olga , de Vries Elisabeth G.E.
Published: April 2023

MIP images of all subjects
Supplementary Figure 7 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Authors: Ali Aesha I. , Wang Minyu , von Scheidt Bianca , Dominguez Pilar M. , Harrison Aaron J. , Tantalo Daniela G.M. , Kang Jian , Oliver Amanda J. , Chan Jack D. , Du Xin , Bai Yuchen , Lee Belinda , Johnstone Ricky W. , Darcy Phillip K. , Kershaw Michael H. , Slaney Clare Y.
Published: April 2023

Supplementary Figure 7. No cytokine storm was observed in WAP- and MMTV-Her2 mice post the ACTIV+Pano treatment.
Supplementary Figure 3 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Authors: Ali Aesha I. , Wang Minyu , von Scheidt Bianca , Dominguez Pilar M. , Harrison Aaron J. , Tantalo Daniela G.M. , Kang Jian , Oliver Amanda J. , Chan Jack D. , Du Xin , Bai Yuchen , Lee Belinda , Johnstone Ricky W. , Darcy Phillip K. , Kershaw Michael H. , Slaney Clare Y.
Published: April 2023

Supplementary Figure 3. Pano induced pancreatic tumor cell apoptosis.
Supplementary Appendix from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Authors: Chakraborty Goutam , Patail Nabeela Khan , Hirani Rahim , Nandakumar Subhiksha , Mazzu Ying Z. , Yoshikawa Yuki , Atiq Mohammad , Jehane Lina E. , Stopsack Konrad H. , Lee Gwo-Shu Mary , Abida Wassim , Morris Michael J. , Mucci Lorelei A. , Danila Daniel , Kantoff Philip W.
Published: April 2023

Supplementary tables (except Table S3) and figure captions
Figure S3 from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Authors: Chakraborty Goutam , Patail Nabeela Khan , Hirani Rahim , Nandakumar Subhiksha , Mazzu Ying Z. , Yoshikawa Yuki , Atiq Mohammad , Jehane Lina E. , Stopsack Konrad H. , Lee Gwo-Shu Mary , Abida Wassim , Morris Michael J. , Mucci Lorelei A. , Danila Daniel , Kantoff Philip W.
Published: April 2023

Figure S3
Figure 5 from Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Authors: Liu Tingting , Lam Vi , Thieme Elana , Sun Duanchen , Wang Xiaoguang , Xu Fei , Wang Lili , Danilova Olga V. , Xia Zheng , Tyner Jeffrey W. , Kurtz Stephen E. , Danilov Alexey V.
Published: April 2023

BAX overexpression re-sensitizes OCI-:Y3 cells to AZD5991
Supplementary Data from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Log odds ratios
Supp FIgure 7 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure
Figures S1-S2 from Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity
Authors: Sharma Ashwyn K. , de la Torre Jorge , IJzerman Nikki S. , Sutton Thomas L. , Zhao Beiqun , Khan Tahsin M. , Banerjee Sudeep , Cui Christina , Nguyen Vi , Alkhuziem Maha , Snaebjornsson Petur , van Boven Hester , Bruining Annemarie , Tang Chih-Min , Yoon Hyunho , De la Fuente Alexa , Kato Shumei , Patel Hitendra , Heinrich Michael C. , Corless Christopher L. , Horgan Santiago , Burgoyne Adam M. , Fanta Paul , Mesirov Jill P. , Blakely Andrew M. , Davis Jeremy L. , Mayo Skye C. , van Houdt Winan J. , Steeghs Neeltje , Sicklick Jason K.
Published: April 2023

KIT vs non-KIT mutations from NCDB, morphology and age distributions
Table S2 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Authors: Si Han , Kuziora Michael , Quinn Katie J. , Helman Elena , Ye Jiabu , Liu Feng , Scheuring Urban , Peters Solange , Rizvi Naiyer A. , Brohawn Philip Z. , Ranade Koustubh , Higgs Brandon W. , Banks Kimberly C. , Chand Vikram K. , Raja Rajiv
Published: April 2023

Patient-level clinical outcome data (overall survival) and bTMB scores
Supp FIgure 4 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure
Figure S2 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Authors: Si Han , Kuziora Michael , Quinn Katie J. , Helman Elena , Ye Jiabu , Liu Feng , Scheuring Urban , Peters Solange , Rizvi Naiyer A. , Brohawn Philip Z. , Ranade Koustubh , Higgs Brandon W. , Banks Kimberly C. , Chand Vikram K. , Raja Rajiv
Published: April 2023

Performance of germline/somatic betabinomial classifier
Supplementary Data from Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer
Authors: Lundy Joanne , Gao Hugh , Berry William , Masoumi-Moghoddam Samar , Jenkins Brendan J. , Croagh Daniel
Published: April 2023

Supplementary tables and figure
Supplementary Data from A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Authors: Fong Lawrence , Morris Michael J. , Sartor Oliver , Higano Celestia S. , Pagliaro Lance , Alva Ajjai , Appleman Leonard J. , Tan Winston , Vaishampayan Ulka , Porcu Raphaelle , Tayama Darren , Kadel Edward E. , Yuen Kobe C. , Datye Asim , Armstrong Andrew J. , Petrylak Daniel P.
Published: April 2023

Supplementary Figures and Tables
Supplementary Table S2 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Table S2
Supplementary Materials and Methods from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S9 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Fig. S9. Phenotype of NK cells from patients with Hodgkin lymphoma (HL) compared to healthy donors (HD).
Supplementary Table 1 from Aging and CNS Myeloid Cell Depletion Attenuate Breast Cancer Brain Metastasis
Authors: Wu Alex Man Lai , Gossa Selamawit , Samala Ramakrishna , Chung Monika A. , Gril Brunilde , Yang Howard H. , Thorsheim Helen R. , Tran Andy D. , Wei Debbie , Taner Esra , Isanogle Kristine , Yang Yuan , Dolan Emma L. , Robinson Christina , Difilippantonio Simone , Lee Maxwell P. , Khan Imran , Smith Quentin R. , McGavern Dorian B. , Wakefield Lalage M. , Steeg Patricia S.
Published: April 2023

Supplementary Table 1
Supplementary Methods from Aging and CNS Myeloid Cell Depletion Attenuate Breast Cancer Brain Metastasis
Authors: Wu Alex Man Lai , Gossa Selamawit , Samala Ramakrishna , Chung Monika A. , Gril Brunilde , Yang Howard H. , Thorsheim Helen R. , Tran Andy D. , Wei Debbie , Taner Esra , Isanogle Kristine , Yang Yuan , Dolan Emma L. , Robinson Christina , Difilippantonio Simone , Lee Maxwell P. , Khan Imran , Smith Quentin R. , McGavern Dorian B. , Wakefield Lalage M. , Steeg Patricia S.
Published: April 2023

Supplementary Methods
Supplementary Figure S7 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Fig. S7. Addition of AFM13 failed to induce apoptosis of Karpas 299 cells in the absence of NK cells.
Supplementary Figure S6 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Fig. S6. Phenotype of preactivated and expanded CB-NK cells upon AFM13 triggering.
Supplementary Figure S1 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Fig. S1. AFM13 binding to CD30+ tumors triggers cytokine secretion and degranulation of conventional human NK cells.
Supplementary Tables S1-S6 from STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition
Authors: Sitthideatphaiboon Piyada , Galan-Cobo Ana , Negrao Marcelo V. , Qu Xiao , Poteete Alissa , Zhang Fahao , Liu Diane D. , Lewis Whitney E. , Kemp Haley N. , Lewis Jeff , Rinsurongkawong Waree , Giri Uma , Lee J. Jack , Zhang Jianjun , Roth Jack A. , Swisher Stephen , Heymach John V.
Published: April 2023

Supplementary tables S1-S6
Table S1 and Figures S1-10 from Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis
Authors: Holthof Lisa C. , van der Schans Jort J. , Katsarou Afroditi , Poels Renée , Gelderloos Anne T. , Drent Esther , van Hal-van Veen Susan E. , Li Fengzhi , Zweegman Sonja , van de Donk Niels W.C.J. , Themeli Maria , Groen Richard W.J. , Mutis Tuna
Published: April 2023

Table providing information on scFv sequences CARs. Figures providing data on CAR T cell phenotype, BMMSC survival, target antigen expression, cytotoxic mediator measurements, Survivin and Mcl-1 expression in MM cells, effector cell survival, and in vivo efficacy of BCMA-CAR T cells.
Table S3 from Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes
Authors: Altoe Mirella L. , Kalinsky Kevin , Marone Alessandro , Kim Hyun K. , Guo Hua , Hibshoosh Hanina , Tejada Mariella , Crew Katherine D. , Accordino Melissa K. , Trivedi Meghna S. , Hershman Dawn L. , Hielscher Andreas H.
Published: April 2023

Mean baseline â^†_TP1 ã€-ctHHbã€-_N levels for different molecular subgroups and according to pCR status and RCB classification.
Table S2 from Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes
Authors: Altoe Mirella L. , Kalinsky Kevin , Marone Alessandro , Kim Hyun K. , Guo Hua , Hibshoosh Hanina , Tejada Mariella , Crew Katherine D. , Accordino Melissa K. , Trivedi Meghna S. , Hershman Dawn L. , Hielscher Andreas H.
Published: April 2023

Mean baseline ã€-ctTHbã€-_N levels for different molecular subgroups and according to pCR status and RCB classification.
Supplementary Table S3 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

The p values from pairwise comparisons amongst the molecular subtypes for each cohort using the Wilcoxon rank-sum test are shown.
Figure S1 from Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes
Authors: Altoe Mirella L. , Kalinsky Kevin , Marone Alessandro , Kim Hyun K. , Guo Hua , Hibshoosh Hanina , Tejada Mariella , Crew Katherine D. , Accordino Melissa K. , Trivedi Meghna S. , Hershman Dawn L. , Hielscher Andreas H.
Published: April 2023

Reconstructed 3D ctHbT map within the breast bearing the tumor of (Left) a 46-year-old woman (Patient 1)who achieved pCR after NAC for HER2+ breast cancer, and (Right) a 46-year-old woman (Patient 3) and HER2- breast cancer who was classified as RCB III (non-pCR). NAC drug regimen protocol includes 12 cycles of weekly paclitaxel followed by 4 cycles of AC given every 2 weeks. DOTBIS images corresponding to baseline, before the first taxane treatment (T1), before her third and fifth taxane cycle (T3, T5), before her first and second AC cycles (AC1, AC2), and pre-surgery (PS) were arranged from top to bottom. Selected tumor volume is highlighted in contrast to the surrounding volume.
Supplementary Table S1 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

Clinical characteristics of the cohorts included in study. Of note, the Seiler cohort pathological tumor stage is after neoadjuvant chemotherapy (i.e. ypT). ** age > 90 censored to protect patient privacy
Supplementary Figure S9 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

(A) Immunohistochemistry (IHC) staining of NECTIN4 protein in UMUC3-Control and UMUC3-NECTIN4 OE tumor xenografts. (B) Rabbit IgG isotype negative control of UMUC3-Control and UMUC3-NECTIN4 OE tumor xenografts.
supp material from Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
Authors: Martinez-Morilla Sandra , Villarroel-Espindola Franz , Wong Pok Fai , Toki Maria I. , Aung Thazin Nwe , Pelekanou Vasiliki , Bourke-Martin Brian , Schalper Kurt A. , Kluger Harriet M. , Rimm David L.
Published: April 2023

supp material
Supplementary Figure S6 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

(A) Scatter plot of GATA3 versus NECTIN4 mRNA expression demonstrates a positive correlation between GATA3 and NECTIN4 mRNA expression in bladder cancer cell lines, with a Spearman correlation coefficient of 0.595, p=7.4E-5. (Source: DepMap) (B) Distribution of cell dependency scores for NECTIN4 from CRISPR knockout and RNAi knockdown experiments in 625 and 711 cell lines, respectively, which were obtained from DepMap. A score of 0 denotes that the gene is not essential for cell life, whereas -1 denotes that the gene is a common essential gene.
Supplementary Figure S5 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

Association between NECTIN4 mRNA expression and clinical characteristics for the MOL cohort for (A) sex (p=0.61), (B) age (p=0.47), (C) clinical stage (p=0.063), and (D) pathological stage (p=0.012). The p value from Kruskal-Wallis testing is shown for each panel.
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Authors: Najjar Yana G. , McCurry Dustin , Lin Huang , Lin Yan , Zang Yan , Davar Diwakar , Karunamurthy Arivarasan , Drabick Joseph J. , Neves Rogerio I. , Butterfield Lisa H. , Ernstoff Marc S. , Puzanov Igor , Skitzki Joseph J. , Bordeaux Jennifer , Summit IlaSri B. , Bender Jehovana O. , Kim Ju Young , Chen Beiru , Sarikonda Ghanashyam , Pahuja Anil , Tsau Jennifer , Alfonso Zeni , Laing Christian , Pingpank James F. , Holtzman Matthew P. , Sander Cindy , Rose Amy , Zarour Hassane M. , Kirkwood John M. , Tarhini Ahmad A.
Published: April 2023

Treatment significantly affects the circulating immune compartment.
Supplementary Figure S1 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

NECTIN4 mRNA gene expression across the (A) TCGA, (B) Decipher, and (C) Lund molecular subtypes in the Decipher commercial cohort (n=529). The p value from Kruskal-Wallis testing is shown for each panel.
Figure S5 from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

Supplementary Figure 5. γ-Secretase activity of different mouse tissues. The membrane fractions of tissues were prepared to determine γ-secretase activity. (n=4)
Supplementary Figure 2 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Authors: DeCensi Andrea , Puntoni Matteo , Johansson Harriet , Guerrieri-Gonzaga Aliana , Caviglia Silvia , Avino Franca , Cortesi Laura , Ponti Antonio , Pacquola Maria Grazia , Falcini Fabio , Gulisano Marcella , Digennaro Maria , Cariello Anna , Cagossi Katia , Pinotti Graziella , Lazzeroni Matteo , Serrano Davide , Briata Irene Maria , Buttiron Webber Tania , Boni Luca , Bonanni Bernardo
Published: April 2023

Adherence by smoking status.
Table S1 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
Authors: Qu Yuan-Yuan , Zhang Hai-Liang , Guo Hongqian , Luo Hong , Zou Qing , Xing Nianzeng , Xia Shujie , Sun Zhongquan , Zhang Xuepei , He Chaohong , Cai Jinling , Zhang Xiao , Wang Quanren , Ye Ding-Wei
Published: April 2023

Serious treatment-related adverse events
Supplementary Table S8-S12 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Table S8-S12 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure 3 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Authors: Sharma Priyanka , Abramson Vandana G. , O'Dea Anne , Nye Lauren , Mayer Ingrid , Pathak Harsh B. , Hoffmann Marc , Stecklein Shane R. , Elia Manana , Lewis Sharon , Scott Jecinta , De Jong Jilliann A. , Wang Yen Y. , Yoder Rachel , Schwensen Kelsey , Finke Karissa , Heldstab Jaimie , LaFaver Stephanie , Williamson Stephen K. , Phadnis Milind A. , Reed Gregory A. , Kimler Bruce F. , Khan Qamar J. , Godwin Andrew K.
Published: April 2023

Gene expression signatures by PIK3CA mutation status
Supplementary Figure 2 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Authors: Sharma Priyanka , Abramson Vandana G. , O'Dea Anne , Nye Lauren , Mayer Ingrid , Pathak Harsh B. , Hoffmann Marc , Stecklein Shane R. , Elia Manana , Lewis Sharon , Scott Jecinta , De Jong Jilliann A. , Wang Yen Y. , Yoder Rachel , Schwensen Kelsey , Finke Karissa , Heldstab Jaimie , LaFaver Stephanie , Williamson Stephen K. , Phadnis Milind A. , Reed Gregory A. , Kimler Bruce F. , Khan Qamar J. , Godwin Andrew K.
Published: April 2023

Kaplan-Meier estimates of progression-free survival by baseline metabolic status
Supplementary Table S1 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Table S1 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure 9 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

PanINs of KC mice pancreas show elevated expression of DLAT
Supplementary Figure 4 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

Induction of ADM in KC mice pancreas with Cerulean treatment.
Supplementary Data from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Data from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure 16 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

SR18292, an inhibitor of PGC1α reduces IPMN organoid growth
Supplementary Figure 11 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

The role of PGC1α on tumorigenicity and stemness of PDAC cells.
Supplementary Figure 1 from PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions
Authors: Nimmakayala Rama Krishna , Rauth Sanchita , Chirravuri Venkata Ramakanth , Marimuthu Saravanakumar , Nallasamy Palanisamy , Vengoji Raghupathy , Lele Subodh M. , Rachagani Satyanarayana , Mallya Kavita , Malafa Mokenge P. , Ponnusamy Moorthy P. , Batra Surinder K.
Published: April 2023

PanIN and IPMN show stemness signatures.
Supplementary Figure S9 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S9 shows the correlation between serum prostate-specific antigen (PSA) levels and plasma circulating tumor DNA fraction.
Supplementary Figure S8 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S8 shows that exome-wide sequencing supports ctDNA fraction estimates inferred with the 72-gene panel
Supplementary Figure 3 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Authors: Crabb Simon J. , Danson Sarah , Catto James W.F. , Hussain Syed , Chan Danna , Dunkley Denise , Downs Nichola , Marwood Ellice , Day Laura , Saunders Geoff , Light Michelle , Whitehead Amy , Ellis Deborah , Sarwar Naveed , Enting Deborah , Birtle Alison , Johnson Bernadette , Huddart Robert , Griffiths Gareth
Published: April 2023

Supplementary Figure 3 shows promotor methylation status for the indicated genes in cfDNA
Supplementary Figure S25 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S25 shows concordant identification of intragenic copy number changes inside the androgen receptor (AR) gene based on a coverage-based approach and breakpoint-based approach
Supplementary Figure 1 from Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Authors: Crabb Simon J. , Danson Sarah , Catto James W.F. , Hussain Syed , Chan Danna , Dunkley Denise , Downs Nichola , Marwood Ellice , Day Laura , Saunders Geoff , Light Michelle , Whitehead Amy , Ellis Deborah , Sarwar Naveed , Enting Deborah , Birtle Alison , Johnson Bernadette , Huddart Robert , Griffiths Gareth
Published: April 2023

Supplementary Figure 1 shows a schematic of the treatment cycle
Supplementary Figure S21 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S21 shows per patient absolute AR gene copy number and number of mutant AR copies at different cell-free DNA collection timepoints
Supplementary Data from Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Authors: Davids Matthew S. , Roberts Andrew W. , Kenkre Vaishalee P. , Wierda William G. , Kumar Abhijeet , Kipps Thomas J. , Boyer Michelle , Salem Ahmed Hamed , Pesko John C. , Arzt Jennifer A. , Mantas Margaret , Kim Su Y. , Seymour John F.
Published: April 2023

Supplementary Data from Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Supplementary Figure 1 from FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC
Authors: Bickett Thomas E. , Knitz Michael , Darragh Laurel B. , Bhatia Shilpa , Van Court Benjamin , Gadwa Jacob , Bhuvane Shiv , Piper Miles , Nguyen Diemmy , Tu Hua , Lenz Laurel , Clambey Eric T. , Barry Kevin , Karam Sana D.
Published: April 2023

Supplementary Figure 1 (A) Flow cytometry analysis of NK cell population expression of NKG2A in MOC2 tumors 3 days after RT; n=3. (B). Flow cytometry analysis of NK cell populations in MOC2 tumors 3 days after RT and anti-NKG2A therapy; n=6. (C) Flow cytometry analysis of CD4 T cell populations in MOC2 tumors 3 days after RT, anti-NKG2A therapy and NK cell depletion with NK1.1 antibody; n=6. (D) MOC2 tumor volumes of C57BL/6 mice treated with RT and isotype control (red line), anti-CD137, anti-CD25, and anti-NKG2A (blue line), anti-CD17 and antiCD25 (black line); n=7.
Table S3 from Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells
Authors: Pan Wenting , Zhang Zhouwei , Kimball Hannah , Qu Fangfang , Berlind Kyler , Stopsack Konrad H. , Lee Gwo-Shu Mary , Choueiri Toni K. , Kantoff Philip W.
Published: April 2023

Table S3. Differential express genes enrichment analysis in LNCaP-abl-AAr and LNCaP-abl. ES= enrichment score, NES= normalized enrichment score, NOM = nominal, FDR = false discovery rate. The significant related genes were defined with an NOM p-val less than 0.01 and FDR q-val less than 0.25.
Table S2 from Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells
Authors: Pan Wenting , Zhang Zhouwei , Kimball Hannah , Qu Fangfang , Berlind Kyler , Stopsack Konrad H. , Lee Gwo-Shu Mary , Choueiri Toni K. , Kantoff Philip W.
Published: April 2023

Table S2. Differential express genes enrichment analysis in LAPC4-AAr and LAPC4.ES= enrichment score, NES= normalized enrichment score, NOM = nominal, FDR = false discovery rate. The significant related genes were defined with an NOM p-val less than 0.01 and FDR q-val less than 0.25.
Supplementary materials-Clinical trial protocol from Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Authors: Wu Jing , Yuan Ying , Long Priel Debra A. , Fink Danielle , Peer Cody J. , Sissung Tristan M. , Su Yu-Ting , Pang Ying , Yu Guangyang , Butler Madison K. , Mendoza Tito R. , Vera Elizabeth , Ahmad Salman , Bryla Christine , Lindsley Matthew , Grajkowska Ewa , Mentges Kelly , Boris Lisa , Antony Ramya , Garren Nancy , Siegel Christine , Lollo Nicole , Cordova Christine , Aboud Orwa , Theeler Brett J. , Burton Eric M. , Penas-Prado Marta , Leeper Heather , Gonzales Javier , Armstrong Terri S. , Calvo Katherine R. , Figg William D. , Kuhns Douglas B. , Gallin John I. , Gilbert Mark R.
Published: April 2023

Clinical trial protocol